Y-Intercept (HK)’s Atrium Therapeutics RNA Stock Holding History

Y-Intercept (HK)’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-35,103	Closed	-$472K	–	2237
2026 Q2	$472K	Buy	+35,103	New	+$459K	0.01%	1330

Other funds holding RNA

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FIA

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Y-Intercept (HK)'s RNA Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 35,103 shares — an estimated $472K sold.

Y-Intercept (HK) first reported a position in RNA in Q2 2026 and held it in 1 quarter. The position peaked at $472K in Q2 2026. 9 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

Y-Intercept (HK) reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 35,103 Atrium Therapeutics shares in Q3 2026, an estimated $472K.
Y-Intercept (HK) first reported a position in Atrium Therapeutics in Q2 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Atrium Therapeutics position peaked at $472K in Q2 2026.
9 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.